Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia
Video navigation menu
Fundamental principles for LDL-c-lowering therapy 04:00
Treatment goals for LDL-c across categories of total CVD risk 06:31
Recommendations for pharmacological LDL-c lowering 07:32
Recommendations for lipid-lowering therapy in very-high-risk patients with ACS 10:35
Recommendations for treatment of patients with hypertriglyceridemia 13:24
The modern concept of lipid-lowering strategies to reduce CVD 16:44
Educational information
This lecture by prof. François Mach, MD is part of the virtual symposium "Reducing Residual Risk for Cardiovascular Disease: Is there a role for non-LDL lowering agents?" from the German Cardiac Society.
Faculty
Prof. François Mach, MD is cardiologist at the Geneva University Hospital in Switzerland.
Disclosures
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding
Funding for this educational program was provided by an unrestricted educational grant from Amarin.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: